Compare Stocks: PRAX, ALNY, ROIV, and BNTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$223.94 +1.8%	$238.92	$197.81 ▼ $495.55	$29.42B	0.28	1.39 million shs	1.36 million shs
BNTX BioNTech	$95.83 -1.9%	$99.01	$79.52 ▼ $124.00	$24.69B	1.25	877,746 shs	899,354 shs
PRAX Praxis Precision Medicines	$280.14 -1.2%	$332.63	$50.31 ▼ $392.70	$7.92B	2.79	475,285 shs	435,152 shs
ROIV Roivant Sciences	$35.53 -0.7%	$36.64	$15.25 ▼ $42.50	$25.84B	1.1	8.84 million shs	5.74 million shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	+1.84%	-11.86%	-15.85%	-30.78%	-50.46%
BNTX BioNTech	-1.86%	-2.78%	-7.65%	+2.45%	-8.88%
PRAX Praxis Precision Medicines	-1.21%	-0.31%	-20.37%	-15.87%	+449.51%
ROIV Roivant Sciences	-0.70%	-2.66%	+1.72%	-1.55%	+118.51%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$223.94 +1.8%	$238.92	$197.81 ▼ $495.55	$29.42B	0.28	1.39 million shs	1.36 million shs
BNTX BioNTech	$95.83 -1.9%	$99.01	$79.52 ▼ $124.00	$24.69B	1.25	877,746 shs	899,354 shs
PRAX Praxis Precision Medicines	$280.14 -1.2%	$332.63	$50.31 ▼ $392.70	$7.92B	2.79	475,285 shs	435,152 shs
ROIV Roivant Sciences	$35.53 -0.7%	$36.64	$15.25 ▼ $42.50	$25.84B	1.1	8.84 million shs	5.74 million shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	+1.84%	-11.86%	-15.85%	-30.78%	-50.46%
BNTX BioNTech	-1.86%	-2.78%	-7.65%	+2.45%	-8.88%
PRAX Praxis Precision Medicines	-1.21%	-0.31%	-20.37%	-15.87%	+449.51%
ROIV Roivant Sciences	-0.70%	-2.66%	+1.72%	-1.55%	+118.51%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALNY Alnylam Pharmaceuticals	2.83	Moderate Buy	$366.90	63.84% Upside
BNTX BioNTech	2.68	Moderate Buy	$126.00	31.49% Upside
PRAX Praxis Precision Medicines	2.95	Moderate Buy	$613.26	118.91% Upside
ROIV Roivant Sciences	2.85	Moderate Buy	$45.64	28.44% Upside

Current Analyst Ratings Breakdown

Latest PRAX, ALNY, ROIV, and BNTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/6/2026	PRAX Praxis Precision Medicines	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$1,201.00
10/6/2026	PRAX Praxis Precision Medicines	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$810.00 ➝ $826.00
10/2/2026	BNTX BioNTech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/30/2026	ALNY Alnylam Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
9/30/2026	ALNY Alnylam Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$375.00 ➝ $369.00
9/24/2026	ROIV Roivant Sciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/24/2026	PRAX Praxis Precision Medicines	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$1,201.00
9/24/2026	PRAX Praxis Precision Medicines	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$582.00
9/21/2026	ALNY Alnylam Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$455.00
9/16/2026	ROIV Roivant Sciences	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$51.00
9/16/2026	BNTX BioNTech	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy

(Data available from 10/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALNY Alnylam Pharmaceuticals	$3.71B	8.07	$2.85 per share	78.64	$5.97 per share	37.51
BNTX BioNTech	$3.25B	7.46	$1.31 per share	73.13	$96.59 per share	0.99
PRAX Praxis Precision Medicines	$8.55M	914.80	N/A	N/A	$34.85 per share	8.04
ROIV Roivant Sciences	$7.53M	3,407.35	N/A	N/A	$7.35 per share	4.83

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALNY Alnylam Pharmaceuticals	$313.75M	$5.38	41.62	23.09	N/A	15.26%	84.93%	14.30%	10/29/2026 (Estimated)
BNTX BioNTech	-$1.29B	-$7.83	N/A	N/A	N/A	-63.54%	-6.86%	-6.00%	11/3/2026 (Estimated)
PRAX Praxis Precision Medicines	-$303.27M	-$12.93	N/A	N/A	N/A	N/A	-34.15%	-32.42%	11/9/2026 (Estimated)
ROIV Roivant Sciences	-$299.77M	-$0.53	N/A	N/A	N/A	-3,534.96%	-22.94%	-21.53%	11/9/2026 (Estimated)

Latest PRAX, ALNY, ROIV, and BNTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/3/2026	Q3 2026	BNTX BioNTech	$0.8380	N/A	N/A	N/A	$1.20 billion	N/A
10/29/2026	Q3 2026	ALNY Alnylam Pharmaceuticals	$1.77	N/A	N/A	N/A	$1.43 billion	N/A
8/7/2026	Q1 2027	ROIV Roivant Sciences	-$0.2996	-$0.26	+$0.0396	-$0.26	$2.06 million	$1.44 million
8/6/2026	Q2 2026	PRAX Praxis Precision Medicines	-$3.67	-$2.87	+$0.80	-$2.87	$1.25 million	N/A
8/4/2026	Q2 2026	BNTX BioNTech	-$2.3983	-$2.5340	-$0.1357	-$3.70	$180.18 million	$122.31 million
7/30/2026	Q2 2026	ALNY Alnylam Pharmaceuticals	$1.63	$1.84	+$0.21	$1.21	$1.32 billion	$1.29 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALNY Alnylam Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BNTX BioNTech	N/A	N/A	N/A	N/A	N/A
PRAX Praxis Precision Medicines	N/A	N/A	N/A	N/A	N/A
ROIV Roivant Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALNY Alnylam Pharmaceuticals	0.75	3.05	2.99
BNTX BioNTech	0.01	7.85	7.80
PRAX Praxis Precision Medicines	N/A	15.73	15.73
ROIV Roivant Sciences	N/A	16.72	16.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALNY Alnylam Pharmaceuticals	92.97%
BNTX BioNTech	15.52%
PRAX Praxis Precision Medicines	67.84%
ROIV Roivant Sciences	64.76%

Insider Ownership

Company	Insider Ownership
ALNY Alnylam Pharmaceuticals	0.86%
BNTX BioNTech	19.20%
PRAX Praxis Precision Medicines	3.00%
ROIV Roivant Sciences	8.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALNY Alnylam Pharmaceuticals	2,770	133.81 million	132.66 million	Optionable
BNTX BioNTech	7,807	252.88 million	204.33 million	Optionable
PRAX Praxis Precision Medicines	168	27.92 million	27.08 million	Optionable
ROIV Roivant Sciences	721	722.32 million	658.76 million	Optionable

PRAX, ALNY, ROIV, and BNTX Headlines

Recent News About These Companies

Roivant Sciences Ltd. (NASDAQ:ROIV) Stock Has Consensus Target Price of $45.64

1 hour ago | americanbankingnews.com

Roivant Sciences Ltd. (NASDAQ:ROIV) Stock Now Rated "Moderate Buy" by Sell-Side Brokerages

1 hour ago | marketbeat.com

Comparing Janux Therapeutics (NASDAQ:JANX) and Roivant Sciences (NASDAQ:ROIV)

October 6 at 6:15 AM | americanbankingnews.com

Roivant Sciences (NASDAQ:ROIV) Director Sells 17,750 Shares of Company Stock

October 6 at 4:22 AM | insidertrades.com

Roivant Sciences (NASDAQ:ROIV) Stock: Insider Melissa Epperly Sells 17,750 Shares

October 5 at 7:07 PM | marketbeat.com

Roivant's Eric Venker sells 200,000 shares after option exercise (NASDAQ: ROIV)

October 5 at 3:02 AM | americanbankingnews.com

Roivant, the ‘inveterate drug hunters’, enters commercial era with Lisraya

October 5 at 2:22 AM | biospace.comB

Roivant’s Eric Venker sells 200,000 shares after option exercise (NASDAQ: ROIV)

October 4 at 12:00 PM | defenseworld.netD

Roivant Sciences (NASDAQ:ROIV) CEO Eric Venker Sells 200,000 Shares of Company Stock

October 3, 2026 | americanbankingnews.com

Roivant Sciences (NASDAQ:ROIV) CEO Eric Venker Sells 200,000 Shares of Stock

October 3, 2026 | insidertrades.com

Roivant Sciences (NASDAQ:ROIV) CEO Sells 200,000 Shares of Company Stock

October 2, 2026 | marketbeat.com

Roivant Sciences Targets LISRAYA Launch, Key Pipeline Readouts in Next 12 Months

September 28, 2026 | marketbeat.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Roivant Sciences (ROIV) and Johnson & Johnson (JNJ)

September 27, 2026 | theglobeandmail.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Roivant Sciences (ROIV) and Johnson & Johnson (JNJ)

September 27, 2026 | theglobeandmail.com

Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Roivant Sciences (ROIV)

September 24, 2026 | theglobeandmail.com

Roivant’s Lung Drug Clears Phase 2 Test: Is Another Major Pipeline Asset Emerging?

September 24, 2026 | finance.yahoo.com

Roivant's Immunovant Unit to Stop IMVT-1402 Development in Cutaneous Lupus Erythematosus

September 23, 2026 | finance.yahoo.com

Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus

September 23, 2026 | globenewswire.com

Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus

September 23, 2026 | globenewswire.com

Transcript : Roivant Sciences Ltd. Presents at Bank of America Global Healthcare Conference 2026, Sep-22-2026 12:20 PM

September 22, 2026 | marketscreener.comM

Roivant (ROIV): $9 Billion Sales Potential Faces a Commercialization Test

September 22, 2026 | insidermonkey.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRAX, ALNY, ROIV, and BNTX Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

$223.94 +4.05 (+1.84%)

Closing price 10/6/2026 04:00 PM Eastern

Extended Trading

$223.97 +0.03 (+0.01%)

As of 04:58 AM Eastern

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

BioNTech NASDAQ:BNTX

$95.82 -1.82 (-1.86%)

Closing price 10/6/2026 03:59 PM Eastern

Extended Trading

$95.47 -0.36 (-0.37%)

As of 05:40 AM Eastern

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Praxis Precision Medicines NASDAQ:PRAX

$280.14 -3.42 (-1.21%)

Closing price 10/6/2026 04:00 PM Eastern

Extended Trading

$277.50 -2.64 (-0.94%)

As of 04:01 AM Eastern

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Roivant Sciences NASDAQ:ROIV

$35.53 -0.25 (-0.70%)

Closing price 10/6/2026 04:00 PM Eastern

Extended Trading

$35.60 +0.06 (+0.18%)

As of 05:43 AM Eastern

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PRAX, ALNY, ROIV, and BNTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PRAX, ALNY, ROIV, and BNTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PRAX, ALNY, ROIV, and BNTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRAX, ALNY, ROIV, and BNTX Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

BioNTech NASDAQ:BNTX

Praxis Precision Medicines NASDAQ:PRAX

Roivant Sciences NASDAQ:ROIV

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PRAX, ALNY, ROIV, and BNTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PRAX, ALNY, ROIV, and BNTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PRAX, ALNY, ROIV, and BNTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRAX, ALNY, ROIV, and BNTX Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

BioNTech NASDAQ:BNTX

Praxis Precision Medicines NASDAQ:PRAX

Roivant Sciences NASDAQ:ROIV

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools